FDA Grants Priority Review to AstraZeneca and Daiichi Sankyo's Enhertu for HER2+ Solid Tumors
Enhertu has been approved by the FDA for indications in breast cancer, non-small cell lung cancer, and gastroesophageal junction adenocarcinoma.
August 16, 2026
Breaking News
Can an Office harassment lawyer negotiate a settlement? |
Why is Jack Bodenstein gaining attention? |
Which 100 Series Dash Mats offer the best fit and protection? |
Is oven repair Ottawa worth it for older electric and gas ovens? |
How often should organizations conduct a cloud penetration test? |
